Day: March 15, 2022

WASHINGTON, March 15, 2022 (GLOBE NEWSWIRE) — FTI Consulting Inc. (NYSE: FCN) today announced the appointment of Tom Becker as a Senior Managing Director in the Crisis and Litigation Communications practice within the firm’s Strategic Communications segment. Mr. Becker, who will be based in New York and report to Myron Marlin, Americas Head of the Crisis and Litigation Communications practice, has a wealth of experience in the field, having spent over 15 years as a senior executive with Sitrick and Company. He has advised hundreds of clients across the globe on sensitive and critical matters, including the largest defamation case to go to trial in U.S. history and one of the largest Ponzi schemes of all time. In his role, Mr. Becker will work closely with FTI Consulting’s crisis communications experts across the globe to advise...

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal. Ms. Boni has more than 20 years of legal experience spanning the biopharmaceutical and medical device industries. “Teri is an impressive leader who brings deep legal and business acumen combined with a passion for improving the lives of patients, and we are delighted to welcome her to Surface,” said Rob Ross, M.D., chief executive officer. “Her extensive life-science experience will be a tremendous asset to us as we advance our ongoing clinical trials evaluating the broad potential of our anti-IL-27 antibody, SRF388,...

Figure 1 (a) and (b): Beartrack-Arnett 2022 Drill Target Location MapsFigure 1 (a) and (b): Beartrack-Arnett 2022 Drill Target Location MapsTORONTO, March 15, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), is pleased to provide the following exploration and development update for the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA.A new mineral resource estimate for Beartrack-Arnett is expected by the end of April. Updated grade domains and economic parameters have been finalized. Block model and constrained resource estimation work by the Company’s consultant, Wood, is in its final stages. Column leach test work in support of a Pre-Feasibility Study (“PFS”) on the heap leach aspect of Beartrack-Arnett continues at SGS Lakefield...

Global technology leader signs 328,000 square foot, 16-year lease to establish new NYC Hub in Manhattan’s Flatiron District NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that International Business Machines Corporation (“IBM”) has signed a 16-year, 328,000 square foot lease at One Madison Avenue covering portions of floors 2 and 7, entire floors 8 through 10 and a portion of the ground floor where IBM will have an exclusive lobby entrance creating a building within a building experience. This lease follows the recently announced 20-year, 56,000 square foot lease with Chelsea Piers Fitness. One Madison Avenue is SL Green’s latest world-class development scheduled for completion in November 2023. The 1.4 million square-foot Midtown South office...

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m. – Noon ET on March 22, 2022. This event will include presentations by key opinion leaders who will provide background information on tinnitus and hearing loss, and review the positive Phase 1/2 trial results for Otonomy’s OTO-313 and OTO-413 product candidates that target these conditions. Additionally, members of Otonomy’s senior management team will provide an update on ongoing clinical trials and outline next steps for these programs. External speakers participating in this event include:Barbara Shinn-Cunningham, Ph.D., Director, Carnegie Mellon Neuroscience Institute...

Figure 1 Tête Nord LocationFigure 2 Heliborne EM SurveyFigure 3 Savane Magmatic SystemFigure 4 Rochette ShowingMONTREAL, March 15, 2022 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the commencement of an important helicopter-borne electromagnetic VTEM-type (“VTEM”) survey covering the Tete Nord nickel-copper (“Ni-Cu”) property. This property, currently wholly owned by Midland, is subject to an option agreement signed in December 2021 with Rio Tinto Exploration Canada Inc. (“RTEC”) and is located near the town of La Tuque in Quebec. Regional VTEM survey The VTEM survey is scheduled to begin mid-March and will total approximately 6,700-line kilometres, covering the entire property under option with flight lines at a 100-metre spacing. A budget of $900,000 has been set...

LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global, proprietary online marketplace connecting scientists with healthcare providers to search for biospecimens needed for medical research, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in Maxim Group’s 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022. Dr. Ianelli’s corporate presentation will be available on-demand starting Monday, March 28, 2022, at 9:00 a.m. ET for all registrants of the virtual conference. To attend, please register here. For more information about the Maxim conference, or to schedule a one-on-one meeting with iSpecimen’s management, please contact your appropriate Maxim representative directly, or send an...

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it will present MRD (molecular residual disease) clinical data on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at the following two sessions of American Association for Cancer Research (AACR) Annual Meeting on April 8, 2022:5916 – Tumor-informed patient-specific panel outperforms tumor-naïve and tumor-informed fixed panel for circulating tumor DNA (ctDNA)-based postoperative monitoring of non-small cell lung cancer (NSCLC); and 5917 – Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of patients with stages I-III colorectal cancer (CRC).“We are excited to present the first set of data on our proprietary...

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer. March 15th, 2022 Dear Shareholders, Colleagues and Business Partners: The recently completed 2021 year was a transformational period for Kamada in our path toward becoming a global leader in the plasma-derived specialty market. Following the completion of the planned manufacturing transition of Glassia® to Takeda, our recent acquisition of four FDA-approved commercial immunoglobulins and the establishment of Kamada Plasma, our U.S. based plasma collection company, we are embarking on a new and exciting chapter in the Company’s evolution. We are building...